Status:
UNKNOWN
Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide
Lead Sponsor:
Assiut University
Conditions:
Ovarian Failure
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
The use of adjuvant chemotherapy in younger women with early breast cancer (EBC) has substantially improved the long-term outcome. However, this benefit is associated with long-term toxic effects whic...
Detailed Description
In this phase II trial, patients will be randomly assigned, in a 1:1 ratio, to standard adjuvant or neoadjuvant chemotherapy with the GnRH agonist goserelin (goserelin group) or to chemotherapy withou...
Eligibility Criteria
Inclusion
- Premenopausal cancer patients who will receive Cyclophosphamide-containing chemotherapy.
Exclusion
- postmenopausal cancer patients. cancer patients who will receive non Cyclophosphamide containing chemotherapy.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03475758
Start Date
March 1 2018
End Date
March 1 2020
Last Update
March 23 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.